DOCSLIB.ORG

MOLECULAR GENETIC ANALYSES Male (DNA Analyses) Female

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Patient data (please fill out clearly inblock letters) Family name 160065170067 First name Date of birth Day Month Year Request form Id. No. Age MOLECULAR GENETIC ANALYSES male (DNA Analyses) female Client data Center for Human Genetics Ingelheim Konrad-Adenauer-Str. 17 55218 Ingelheim, Germany Physician Phone +49-6132-781-433, -203, -224, -165 or -578 Fax +49-6132-781-298 or -236 E-mail: [email protected] [email protected] Website: www.bioscientia.com Sample type EDTA blood Amniotic fluid Umbilical cord blood DNA Chorionic villi others, please specify Number of tubes sent Sampling date Indication - Clinical data Please note that detailed pedigree and clinical information is important for interpretation of results. Please provide the following information: Parental consanguinity yes no Patient/proband is affected yes no Family members affected yes no if yes, who Clinical data (medical history, report copies welcome) Ethnic origin Caucasian Asia French Canadian/Acadian Other Middle East Ashkenazi/Jewish Finnish In our lab we offer different testing panels by Next-Generation Sequencing (NGS). The spectrum covered by these panels is being extended constantly. For further information, please contact us (+49 6132-781-433). Declaration of Informed Consent I agree that my test results will not be destroyed after 10 - Please delete as appropriate - With my signature, I declare that I was briefed on years (as is requested by law) to allow my family access to them in the event of my death. Place, date: _____._____._____ I consent to the results of the tests being made available to the following persons in addition to the doctor who submitted ________________________________________ ___________________________________________ them: (physician) Name of patient / legal representative: about the nature, importance and implications of the ________________________________________________ genetic test and that I give my consent to the following I hereby agree to the transfer, in accordance with § 950 BGB, ________________________________________ genetic analysis and to the collection of the blood or of any test material remaining at the end of the analysis to the tissue samples needed for this purpose: laboratory that carried out the analysis and I consent to its Signature of patient / legal representative: use for scientific purposes in pseudoanonymized form. ___________________________________________ I consent to the communication of my data to a medical bil- ___________________________________________ I consent to the storage, in accordance with legal ling clearing house for invoicing purposes. requirements, of the recorded data in paper and/or I am aware that I may withdraw this consent at any time, ver- electronic form and to their use and/or publication in bally or in writing, without giving reasons and without this pseudoanonymized form for scientific purposes for having any adverse consequences for me. quality assurance. 04.2013 · Reproduction prohibited. 5-13-0623 j This label should be stuck onto the attached copy and kept for your Copyright bioscientia records. DO NOT SEND TO US. specimen material specimen material specimen material specimen material specimen material specimen material Array-CGH (specific form available) NEXT-GENERATION SEQUENCING (NGS) PANELS Eye (retinal) panels Kidney/Liver panels Other ciliopathy panels Leber congenital amaurosis (LCA) Polycystic kidney diseases Bardet-Biedl syndrome/ Retinitis pigmentosa, autosomal dominant (ADPKD/ARPKD) Alstrom syndrome Retinitis pigmentosa, autosomal recessive Nephronophthisis (NPHP)/ Joubert syndrome Cone-rod dystrophy UMOD-related disorders Meckel-Gruber syndrome Senior-Loken syndrome Senior-Loken syndrome Jeune syndrome (ATD) Renal hypo-/dysplasia/agenesis/CAKUT Ellis-van-Crefeld syndrome (EVC) Deafness panels Renal tubular dysgenesis (RTD) Sensenbrenner syndrome (CED) Deafness, autosomal dominant Nephrotic syndrome (SRNS) Filamin diseases Deafness, autosomal recessive Focal segmental glomerulosclerosis (FSGS) Primary ciliary dyskinesia (PCD)/ Deafness, X-linked Alport syndrome Kartagener syndrome Usher syndrome Hemolytic uremic syndrome (aHUS)/ Jervell- and Lange-Nielsen syndrome, DDD/MPGN Other NGS-panels SANDD syndrome Polycystic liver diseases (PCLD) Neurofibromatosis (NF) Tuberous Sclerosis (TSC) Skeletal/Connective tissue panels Alport syndrome Marfan syndrome and related diseases MODY diabetes Ehlers-Danlos syndrome Osteogenesis imperfecta Osteopetrosis, autosomal recessive Filamin diseases All genes analysed by NGS can still be examined by conventional Sanger-sequencing (see below). MOLECULAR GENETIC ANALYSES (in alphabetical order) A Gene(s) Aromatic L-aminoacid DDC CHARGE syndrome CHD7 Achondrogenesis, type 2 COL2A1 decarboxylase deficiency* Chloride diarrhea, familial* SLC26A3 Achondroplasia FGFR3 ARPKD PKHD1 Chondrodysplasia type Grebe CDMP1 Acromesomelic dysplasia, type Grebe CDMP1 (see polycystisc kidney disease) Chorea Huntington* HTT Acromesomelic dysplasia, NPR2 Arthrogryposis multiplex congenita* TPM2, TNNI2 Chronic lymphatic leukemia (CLL) IgVH type Maroteaux Arylsulfatase A deficiency* ARSA Ciliary dyskinesia, primary Acute lymphoblastic leukemia* (ALL) Ataxia, autosomal dominant 3 SCA1, SCA2, DNAH5 Acute myeloid leukemia* (AML) SCA3, SCA6, SCA7, SCA17 DNAI1 ADMCKD UMOD Ataxia with isolated TTPA CINCA syndrome NLRP3 (Autosomal dominant medullary Vitamin E deficiency* Cleidocranial dysplasia RUNX2 cystic kidney disease) Ataxia with oculomotor apraxia 1* APTX Clubbing of digits HPGD ADPKD PKD1, PKD2 Ataxia teleangiectasia* ATM COACH syndrome (see polycystic kidney disease) Atypical PKU* (see Joubert syndrome) Adrenal hyperplasia, congenital, CYP21A2 (Tetrahydropterin, BH4-Mangel) Coats disease* NDP due to 21-hydroxylase deficiency Auditory neuropathy Cockayne syndrome* ERCC8, ERCC6 Adrenoleukodystrophy ABCD1 Autoimmune lymphopro- TNFRSF6 Colon carcinoma Afibrinogenemia, congenital* FGA, FGB, FGG liferative syndrome type 1A* non polyposis associated, MLH1, MSH2 Agammaglobulinemia, X-linked* BTK Autoimmune polyendocrine AIRE familial (HNPCC)* Alagille syndrome JAG1 syndrome type 1* poliposis coli, APC, MUTYH Albright syndrome* GNAS Azoospermia* USP9Y familial adenomatous Alexander disease* GFAP Congenital disorder of PMM2 Alkaptonuria* HGD B Gene(s) glycosylation type 1a* Alpha-1 antitrypsin deficiency SERPINA1 Bannayan-Riley-Ruvalcaba syndrome* PTEN Corneal dystrophy DCN Alpha galactosidase A deficiency GLA Bardet-Biedl syndrome 1,2,3 Cornelia-De-Lange syndrome* NIPBL (Fabry disease) BCR/ABL (chronic myeloid leukemia) BCR/ABL CORS syndrome Alpha thalassemia* HBA Beckwith-Wiedemann syndrome (see Joubert syndrome) Alport-like syndrome (Epstein/Fechtner) MYH9 methylation analysis Costello syndrome* HRAS Alport syndrome KvDMR1 and H19-DMR Coumarin resistance VKORC1 X-linked COL4A5 microsatellite analysis UPD(11)pat Cowden syndrome* PTEN autosomal recessive, COL4A3, COL4A4 sequence analysis CDKN1C CDKN1C Cranioectodermal dysplasia autosomal dominant Beta thalassemia* HBB Craniosynostosis, FGFR1, FGFR2, FGFR3 Alstrom syndrome ALMS1 Bloch-Sulzberger syndrome* IKBKG FGFR associated Alzheimer disease* (Incontinentia pigmenti, IP2) Crigler-Najjar syndrome UGT1A1 familial, type 1 APP Bloom syndrome* RECQL3 Crouzon syndrome familial, type 3 PSEN1 (Sister Chromatid Exchange (SCE)) (see Craniosynostosis) Andersen-Tawil syndrome KCNJ2 BOR syndrome 1,3 Cystinosis* CTNS Androgen insensitivity syndrome* AR Brachydactyly type C CDMP1 Cystinuria* Angelman syndrome Breast/Ovarian cancer* BRCA1, BRCA2 Cystic fibrosis 3 CFTR methylation analysis SNRPN SNRPN Brugada syndrome SCN5A most common mutations with OLA microsatellite analysis UPD(15)pat Burkitt lymphoma* MYC Middle-East-Panel sequence analysis UBE3A UBE3A Butyrylcholinesterase deficiency* BCHE Cystic kidney disease Angiotensin I converting enzyme ACE Byler disease ATP8B1 (see polycystic kidney disease) Aniridia PAX6 Cytochrom P450 defects Anonychia RSPO4 C Gene(s) Antley-Bixler syndrome* CADASIL NOTCH3 D Gene(s) Apert syndrome (see Craniosynostosis) Campomelic dysplasia* SOX9 Deafness, autosomal recessive 1,2,3 Apolipoprotein B APOB Canavan syndrome* ASPA GJB2/Cx26 DNFB1 04.2013 · Reproduction prohibited. 5-13-0623 j Apolipoprotein E APOE Carnitine deficiency*, systemic primary SLC22A5 DNFB1 GJB6/Cx30 Apparent mineralcorticoid excess HSD11B2 Carnitine palmitoyl CPT1 Pendred syndrome SLC26A4, FOXI1 Arginase deficiency* ARG1 transferase I deficiency* Deafness, autosomal dominant 1,2,3 Argininosuccinate lyase deficiency* ASL Carnitine palmitoyl CPT2 Dentato-Rubro-Pallido-Luysiane atrophy* ATN1 Argininosuccinate synthetase ASS1 transferase II deficiency* Denys-Drash syndrome WT1 deficiency* Catechol-O methyltransferase activity COMT Desbuquois syndrome CANT1 Copyright bioscientia Aristaless-gene-related disorders* ARX Ceroid lipofuscinosis, neural (all types) 000000000001 Diabetes, (MODY) 3 Hyperkalemic periodic paralysis SCN4A Methylentetrahydrofulate MTHFR Maturity Onset Diabetes of the Young Hyperoxaluria, primary reductase Diabetes insipidus Hyperthyroidism, TSHR Methylmalonic aziduria* MUT Diabetes mellitus, neonatal with GLIS3 familial, non autoimmune Meulengracht syndrome UGT1A1 congenital hypothyroidism Hypochondroplasia FGFR3 Mikrosatellite analysis (maternal Diamond-Blackfan anemia* RPS19 Hypokalemic periodic paralysis CACNA1A, SCN4A contamination of fetal specimen) Dihydropteridine reductase deficiency* QDPR Hypophosphatasia, infantile* ALPL Mitochondrial complex II deficiency* SDHA
Recommended publications
  • Paramyotonia Congenita

    Paramyotonia Congenita

    Paramyotonia congenita Description Paramyotonia congenita is a disorder that affects muscles used for movement (skeletal muscles). Beginning in infancy or early childhood, people with this condition experience bouts of sustained muscle tensing (myotonia) that prevent muscles from relaxing normally. Myotonia causes muscle stiffness that typically appears after exercise and can be induced by muscle cooling. This stiffness chiefly affects muscles in the face, neck, arms, and hands, although it can also affect muscles used for breathing and muscles in the lower body. Unlike many other forms of myotonia, the muscle stiffness associated with paramyotonia congenita tends to worsen with repeated movements. Most people—even those without muscle disease—feel that their muscles do not work as well when they are cold. This effect is dramatic in people with paramyotonia congenita. Exposure to cold initially causes muscle stiffness in these individuals, and prolonged cold exposure leads to temporary episodes of mild to severe muscle weakness that may last for several hours at a time. Some older people with paramyotonia congenita develop permanent muscle weakness that can be disabling. Frequency Paramyotonia congenita is an uncommon disorder; it is estimated to affect fewer than 1 in 100,000 people. Causes Mutations in the SCN4A gene cause paramyotonia congenita. This gene provides instructions for making a protein that is critical for the normal function of skeletal muscle cells. For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of positively charged atoms (ions), including sodium, into skeletal muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells.
  • Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    Primary Cilia in Energy Balance Signaling and Metabolic Disorder

    BMB Rep. 2015; 48(12): 647-654 BMB www.bmbreports.org Reports Invited Mini Review Primary cilia in energy balance signaling and metabolic disorder Hankyu Lee, Jieun Song, Joo Hyun Jung & Hyuk Wan Ko* College of Pharmacy, Dongguk University, Goyang 10326, Korea Energy homeostasis in our body system is maintained by bal- complex, due to many confounding genetics and environ- ancing the intake and expenditure of energy. Excessive accu- mental factors equivocally affecting the progress of the disease. mulation of fat by disrupting the balance system causes over- Moreover, metabolic disorders are interrelated diseases exem- weight and obesity, which are increasingly becoming global plified by the association of obesity with insulin resistance, health concerns. Understanding the pathogenesis of obesity fo- leading to development of type II diabetes (2). Genetic factors cused on studying the genes related to familial types of for obesity are poorly understood, and recent progress by ge- obesity. Recently, a rare human genetic disorder, ciliopathy, nome-wide association studies support the notion of polygenic links the role for genes regulating structure and function of a features of obesity which suggests that multiple genes, tissues cellular organelle, the primary cilium, to metabolic disorder, and pathways contribute to the disease (3, 4). Intriguing subset obesity and type II diabetes. Primary cilia are microtubule of genes associated with obesity cause a dysfunction of pri- based hair-like membranous structures, lacking motility and mary cilia, which results in a rare pleiotropic human disorder functions such as sensing the environmental cues, and trans- called ciliopathy (5, 6). Primary cilia are microtubule based ducing extracellular signals within the cells.
  • The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
  • Disease Reference Book

    Disease Reference Book

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
  • EYE DISEASES July 15-17, 2019

    EYE DISEASES July 15-17, 2019

    International Conference on EYE DISEASES July 15-17, 2019 Venue Sonesta Fort Lauderdale Beach 999 N Fort Lauderdale Beach Blvd Fort Lauderdale, FL Exhibitor Day-1 | Monday July 15, 2019 Keynote Talks Vascular Basement Membrane Thickening in Diabetic Retinopathy Sayon Roy Boston University School of Medicine, Boston, MA Biography Dr. Sayon Roy is a Professor of Medicine and Ophthalmology in Department Ophthalmology, Boston University. He completed his B.S. and M.S. from University of Kalyani, India. He received his PhD from Boston University. Dr. Roy’s seminal work has identified several genes in the retina that are abnormally expressed in diabetic retinopathy. His pioneering work has led to novel gene modulatory techniques in retinal vascular cells using antisense oligonucleotides via intravitreal injection. Dr. Roy has received numerous awards including the American Diabetes Association Research Award for the commitment and dedication towards the fight against diabetes, the 2006 Mentor of the Year Award from Boston University, and the 2008 Innovative Award from the Juvenile Diabetes Research Foundation Does Genomics Play a Role in Diabetic Retinopathy? Arup Das1, Sampath Kumar Rangasamy2, Finny Monickaraj1, David Duggan2, Nicholas Schork2 and Paul McGuire1 1University of New Mexico School of Medicine, Albuquerque, NM 2 Translational and Genomics Research Institute, NM Abstract Genetic risk factors play an important role in the development and progression of diabetic retinopathy (DR). Using a well- defined, clinical phenotype, we have examined the role of rare genetic variants in DR progression, or protection by undertaking whole exome sequencing (WES). We performed WES analysis on two cohorts of patients selected from Diabetic Retinopathy Genomics (DRGen) study population.
  • Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series

    Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series

    DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F.
  • Development of the Stria Vascularis and Potassium Regulation in the Human Fetal Cochlea: Insights Into Hereditary Sensorineural Hearing Loss

    Development of the Stria Vascularis and Potassium Regulation in the Human Fetal Cochlea: Insights Into Hereditary Sensorineural Hearing Loss

    Development of the Stria Vascularis and Potassium Regulation in the Human Fetal Cochlea: Insights into Hereditary Sensorineural Hearing Loss Heiko Locher,1,2 John C.M.J. de Groot,2 Liesbeth van Iperen,1 Margriet A. Huisman,2 Johan H.M. Frijns,2 Susana M. Chuva de Sousa Lopes1,3 1 Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, 2333 ZA, the Netherlands 2 Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, 2333 ZA, the Netherlands 3 Department for Reproductive Medicine, Ghent University Hospital, 9000 Ghent, Belgium Received 25 August 2014; revised 2 February 2015; accepted 2 February 2015 ABSTRACT: Sensorineural hearing loss (SNHL) is dynamics of key potassium-regulating proteins. At W12, one of the most common congenital disorders in humans, MITF1/SOX101/KIT1 neural-crest-derived melano- afflicting one in every thousand newborns. The majority cytes migrated into the cochlea and penetrated the base- is of heritable origin and can be divided in syndromic ment membrane of the lateral wall epithelium, and nonsyndromic forms. Knowledge of the expression developing into the intermediate cells of the stria vascula- profile of affected genes in the human fetal cochlea is lim- ris. These melanocytes tightly integrated with Na1/K1- ited, and as many of the gene mutations causing SNHL ATPase-positive marginal cells, which started to express likely affect the stria vascularis or cochlear potassium KCNQ1 in their apical membrane at W16. At W18, homeostasis (both essential to hearing), a better insight KCNJ10 and gap junction proteins GJB2/CX26 and into the embryological development of this organ is GJB6/CX30 were expressed in the cells in the outer sul- needed to understand SNHL etiologies.
  • Neuromyotonia in Hereditary Motor Neuropathy J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.54.3.230 on 1 March 1991

    Neuromyotonia in Hereditary Motor Neuropathy J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.54.3.230 on 1 March 1991

    230 Journal ofNeurology, Neurosurgery, and Psychiatry 1991;54:230-235 Neuromyotonia in hereditary motor neuropathy J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.3.230 on 1 March 1991. Downloaded from A F Hahn, A W Parkes, C F Bolton, S A Stewart Abstract Case II2 Two siblings with a distal motor This 15 year old boy had always been clumsy. neuropathy experienced cramping and Since the age of 10, he had noticed generalised difficulty in relaxing their muscles after muscle stiffness which increased with physical voluntary contraction. Electromyogra- activity such as walking upstairs, running and phic recordings at rest revealed skating. For some time, he was aware of repetitive high voltage spontaneous elec- difficulty in releasing his grip and his fingers trical discharges that were accentuated tended to cramp on writing. He had noticed after voluntary contraction and during involuntary twitching of his fingers, forearm ischaemia. Regional neuromuscular muscles and thighs at rest and it was more blockage with curare indicated hyperex- pronounced after a forceful voluntary con- citability of peripheral nerve fibres and traction. Muscle cramping and spontaneous nerve block suggested that the ectopic muscle activity were particularly unpleasant activity originated in proximal segments when he re-entered the house in the winter, of the nerve. Symptoms were improved for example, after a game of hockey. Since the with diphenylhydantoin, carbamazepine age of twelve, he had noticed a tendency to and tocainide. trip. Subsequently he developed bilateral foot drop and weakness of his hands. He denied sensory symptoms and perspired only with The term "neuromyotonia" was coined by exertion.
  • Générique Obésités De Causes Rares

    Générique Obésités De Causes Rares

    Protocole National de Diagnostic et de Soins (PNDS) Générique Obésités de causes rares Centre de Référence des maladies rares PRADORT Syndrome de PRADer-Willi et autres Obésités Rares avec Troubles du comportement alimentaire 19 JUILLET 2021 Partie 2 – Argumentaire Cet argumentaire a été élaboré par le Centre de Référence du Syndrome de PRAder-Willi et autres Obésités Rares avec Troubles du comportement alimentaire (PRADORT) . Il a servi de base à l’élaboration du PNDS : Obésités de causes rares. Le PNDS est téléchargeable sur le site de l’HAS, le site du centre de référence PRADORT et le site de la filière DEFISCIENCES CRMR PRADORT 19/07/2021 DéfiScience Filière de santé maladies rares neurdéveloppement 1 Sommaire Liste des abréviations ........................................................................................3 Préambule ........................................................................................................4 Méthode de travail 4 Argumentaire ....................................................................................................5 1.1 Recherche documentaire 5 1.1.1 Base de données et nombre de références 5 1.1.2 Critères de sélection des articles 6 1.2 Sélection des articles 7 1.2.1 Recommandations HAS 7 1.2.2 Articles 10 Annexe 1. Liste des participants ........................................................................108 Annexe 2. Adresses et Coordonnées .................................................................110 Références bibliographiques .............................................................................111
  • Essential Trace Elements in Human Health: a Physician's View

    Essential Trace Elements in Human Health: a Physician's View

    Margarita G. Skalnaya, Anatoly V. Skalny ESSENTIAL TRACE ELEMENTS IN HUMAN HEALTH: A PHYSICIAN'S VIEW Reviewers: Philippe Collery, M.D., Ph.D. Ivan V. Radysh, M.D., Ph.D., D.Sc. Tomsk Publishing House of Tomsk State University 2018 2 Essential trace elements in human health UDK 612:577.1 LBC 52.57 S66 Skalnaya Margarita G., Skalny Anatoly V. S66 Essential trace elements in human health: a physician's view. – Tomsk : Publishing House of Tomsk State University, 2018. – 224 p. ISBN 978-5-94621-683-8 Disturbances in trace element homeostasis may result in the development of pathologic states and diseases. The most characteristic patterns of a modern human being are deficiency of essential and excess of toxic trace elements. Such a deficiency frequently occurs due to insufficient trace element content in diets or increased requirements of an organism. All these changes of trace element homeostasis form an individual trace element portrait of a person. Consequently, impaired balance of every trace element should be analyzed in the view of other patterns of trace element portrait. Only personalized approach to diagnosis can meet these requirements and result in successful treatment. Effective management and timely diagnosis of trace element deficiency and toxicity may occur only in the case of adequate assessment of trace element status of every individual based on recent data on trace element metabolism. Therefore, the most recent basic data on participation of essential trace elements in physiological processes, metabolism, routes and volumes of entering to the body, relation to various diseases, medical applications with a special focus on iron (Fe), copper (Cu), manganese (Mn), zinc (Zn), selenium (Se), iodine (I), cobalt (Co), chromium, and molybdenum (Mo) are reviewed.
  • What Is a Skeletal Muscle Channelopathy?

    What Is a Skeletal Muscle Channelopathy?

    Muscle Channel Patient Day 2019 Dr Emma Matthews The Team • Professor Michael Hanna • Emma Matthews • Doreen Fialho - neurophysiology • Natalie James – clinical nurse specialist • Sarah Holmes - physiotherapy • Richa Sud - genetics • Roope Mannikko – electrophysiology • Iwona Skorupinska – research nurse • Louise Germain – research nurse • Kira Baden- service manager • Jackie Kasoze-Batende– NCG manager • Jean Elliott – NCG senior secretary • Karen Suetterlin, Vino Vivekanandam • – research fellows What is a skeletal muscle channelopathy? Muscle and nerves communicate by electrical signals Electrical signals are made by the movement of positively and negatively charged ions in and out of cells The ions can only move through dedicated ion channels If the channel doesn’t work properly, you have a “channelopathy” Ion channels CHLORIDE CHANNELS • Myotonia congenita – CLCN1 • Paramyotonia congenita – SCN4A MYOTONIA SODIUM CHANNELS • Hyperkalaemic periodic paralysis – SCN4A • Hypokalaemic periodic paralysis – 80% CACNA1S CALCIUM CHANNELS – 10% SCN4A PARALYSIS • Andersen-Tawil Syndrome – KCNJ2 POTASSIUM CHANNELS Myotonia and Paralysis • Two main symptoms • Paralysis = an inexcitable muscle – Muscles are very weak or paralysed • Myotonia = an overexcited muscle – Muscle keeps contracting and become “stuck” - Nerve action potential Cl_ - + - + + + Motor nerve K+ + Na+ Na+ Muscle membrane Ach Motor end plate T-tubule Nav1.4 Ach receptors Cav1.1 and RYR1 Muscle action potential Calcium MuscleRelaxed contraction muscle Myotonia Congenita • Myotonia
  • 2018 Celebration of Research

    2018 Celebration of Research

    UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE 2018 Celebration of Research Welcome from the Dean The annual University of Florida College of Medicine Celebration of Research affords me the opportunity to say Thank You. Thank you for the late nights, the papers written and reviewed, the grant proposals that have been funded and those that will be resubmitted, the patience that you have shown with the varied hurdles placed in the pathway of research. But most importantly, thank you for the passion that you employ to move the boundary of science knowledge forward. Your research vision and the work of your research teams are appreciated and valued. The discoveries and inventions that result from the basic, translational, population and clinical research at our university are transforming medicine. Thank you for your dedication to creating a healthier future for all. The College of Medicine stands proudly behind your efforts. Michael L. Good, MD Dean, UF College of Medicine Celebration of Research 3 POSTER SESSION & RECEPTION Monday, February 19, 2018 5:30pm – 8:30pm Stephen C. O’Connell Center Slow down and smell the roses The 2018 Celebration is already here. Where did the year go? 2017 was indeed another remarkable year of continued growth and progress for research within the College of Medicine, and 2018 is already off to a great start. We have all been running and seem a bit out of breath. Now it is time to slow down and appreciate the breadth and depth of the College of Medicine’s research endeavors and recognize how our research is directed at fundamental, timely, and significant areas of human health.